©The Author(s) 2025.
World J Cardiol. Oct 26, 2025; 17(10): 108594
Published online Oct 26, 2025. doi: 10.4330/wjc.v17.i10.108594
Published online Oct 26, 2025. doi: 10.4330/wjc.v17.i10.108594
Table 2 Recommendations for provocative testing
| COVADIS recommendations for provocative testing[14] |
| Class I (strong indications) |
| History suspicious of VSA without documented episode, especially if: |
| Nitrate-responsive rest angina and/or |
| Marked diurnal variation in symptom onset/exercise tolerance, and/or |
| Rest angina without obstructive coronary artery disease |
| Unresponsive to empiric therapy |
| Acute coronary syndrome presentation in the absence of a culprit lesion |
| Unexplained resuscitated cardiac arrest |
| Unexplained syncope with antecedent chest pain |
| Recurrent rest angina following angiographically successful PCI |
| Class IIa (good indications) |
| Invasive testing for non-invasive diagnosed patients unresponsive to drug therapy |
| Documented spontaneous episode of VSA to determine the ‘site and mode’ of spasm |
| Class IIb (controversial indications) |
| Invasive testing for non-invasive diagnosed patients responsive to drug therapy |
| Class III (contraindications) |
| Emergent acute coronary syndrome |
| Severe fixed multi-vessel coronary artery disease including left main stenosis |
| Severe myocardial dysfunction (Class IIb if symptoms suggestive of vasospasm) |
| Patients without any symptoms suggestive of VSA |
- Citation: Ralota KK, Layland J. Vasospastic angina: Pathophysiology, diagnosis, and emerging therapeutic approaches. World J Cardiol 2025; 17(10): 108594
- URL: https://www.wjgnet.com/1949-8462/full/v17/i10/108594.htm
- DOI: https://dx.doi.org/10.4330/wjc.v17.i10.108594